# Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

> **NCT01923337** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 17 (actual)

## Conditions studied

- Mucinous Adenocarcinoma of the Colon
- Mucinous Adenocarcinoma of the Rectum
- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Signet Ring Adenocarcinoma of the Colon
- Signet Ring Adenocarcinoma of the Rectum
- Stage IIIA Colon Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** alisertib

## Key facts

- **NCT ID:** NCT01923337
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-10-17
- **Final completion:** 2016-10-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923337, "Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01923337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*